Literature DB >> 8156912

Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment.

I Gozes1, A Reshef, D Salah, S Rubinraut, M Fridkin.   

Abstract

The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle17-VIP may be considered useful for the treatment of impotence.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8156912     DOI： 10.1210/endo.134.5.8156912

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


  15 in total

Review 1.  Drugs for the treatment of impotence.

Authors:  L Garcia-Reboll; J P Mulhall; I Goldstein
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

3.  A femtomolar-acting neuroprotective peptide.

Authors:  D E Brenneman; I Gozes
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 4.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

5.  Protection against developmental deficiencies by a lipophilic VIP analogue.

Authors:  I Gozes; M Bachar; A Bardea; A Davidson; S Rubinraut; M Fridkin
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

6.  VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury.

Authors:  E Sigalov; M Fridkin; D E Brenneman; I Gozes
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

7.  VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress.

Authors:  R A Steingart; B Solomon; D E Brenneman; M Fridkin; I Gozes
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

8.  Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides.

Authors:  O Ashur-Fabian; E Giladi; D E Brenneman; I Gozes
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

9.  Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.

Authors:  I Gozes; O Perl; E Giladi; A Davidson; O Ashur-Fabian; S Rubinraut; M Fridkin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

10.  Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain.

Authors:  P Gressens; S Marret; J M Hill; D E Brenneman; I Gozes; M Fridkin; P Evrard
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.